ClinicalTrials.gg
TerminatedNCT04246619BLOSSOMUpdated Apr 7, 2022

Efficacy of Pregabalin and Duloxetine in Patients With PDPN: the Effect of Pain on Cognitive Function, Sleep and Quality of Life

A Phase 4 interventional study of Pregabalin and Duloxetine in Painful Diabetic Peripheral Neuropathy, sponsored by KRKA. Terminated at 13 sites in 5 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-04-07.

Sponsored by KRKA · Phase 4, Interventional, and Treatment

Why this study was terminated
The statistical analysis will still provide relevant results with the same statistical power as initially planned.COVID-19 pandemic prolonged the recruiting period and consequently affected the costs of the clinical trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The objective and the purpose of the trial is to: assess the efficacy of Pregabalin Krka and Dulsevia® in patients with PDPN, investigate the effect of Pregabalin Krka and Dulsevia® on pain and on quality of life (QOL), depression symptoms, cognitive functions, sleep quality and daytime sleepiness and assess the safety of Pregabalin Krka and Dulsevia® in patients with PDPN.

During the 3 months (12 weeks) 5 visits and 2 phone calls are planned.

After the ICF signature and before therapy is allocated, a screening procedure is carried out to verify eligibility: laboratory analyses (concentrations of TSH, vitamin B12, folic acid, glucose, HbA1c, pregnancy test for women of childbearing potential), assessment of PDPN (with questionnaire DN4), assessment of cognition (with questionnaire MoCA), habits, medical history (medical/surgical history and concomitant diseases, previous and/or existing therapy of pain in PDPN, concomitant medications) with measurements and evaluation of pain according to VAS.

On Visit 2 investigator checks the results of laboratory tests, of pregnancy test, measures vital signs, evaluates pain in PDPN according to VAS, checks previous analgesic therapy and concomitant medications.

If patient meets all inclusion and exclusion criteria, he/she is eligible and will be randomly assigned (automatically through electronic version of case report form (eCRF) into two therapy groups (treatment arms) - tretament with Pregabalin Krka OR treatment with Dulsevia®.

Investigator performs assessments of: QoL, sleep quality and daytime sleepiness, depression and adverse events.

At Visit 3, compliance monitoring is done, pain intensity in PDPN by VAS is evaluated, concomitant therapy is checked, vital signs are measured, doses of IMP are adjusted and adverse events assessment are carried out.

At Visit 4, pregnancy test for women of childbearing potential and compliance monitoring are carried out; concomitant medications are checked, vital signs are measured, pain intensity in PDPN by VAS is evaluated, IMP are adjusted and assessment of adverse events is carried out.

At Visit 5 investigator performs again assessments of: QoL, sleep quality and daytime sleepiness, depression, cognition and PDPN. Evaluation of the pain intensity in PDPN by VAS and assessment of the adverse events should be performed. Pregnancy test for women of childbearing potential is carried out.

Read the detailed description

During the 3 months (12 weeks) 5 visits and 2 phone calls are planned.

Procedures and administration:

On arrival at the trial site at Visit 1 the patient receives the complete information on the trial procedures. The patient confirms his decision to participate by signing the informed consent form (ICF). After the ICF signature and before therapy is allocated, a screening procedure is carried out to verify eligibility: laboratory analyses (concentrations of TSH, vitamin B12, folic acid, glucose, HbA1c, pregnancy test for women of childbearing potential), assessment of PDPN (with questionnaire DN4), assessment of cognition (with questionnaire MoCA), habits, medical history (medical/surgical history and concomitant diseases, previous and/or existing therapy of pain in PDPN, concomitant medications) with measurements and evaluation of pain according to VAS.

Patient is instructed not to take any PDPN medication and/or analgesics, if existing on a day of Visit 2.

Information obtained at Visit 1 is input in the eCRF.

Visit 2 (initial baseline visit): 0-7 days after Visit 1

Investigator checks the results of laboratory tests, of pregnancy test, measures vital signs (heart rate, blood pressure), evaluates pain in PDPN according to VAS (separate assessments of current pain intensity, average pain intensity in last 24-h, worst pain intensity in last 24-h, average pain intensity in last 4 weeks and worst pain intensity in last 4 weeks), checks previous analgesic therapy and concomitant medications.

If patient meets all inclusion and exclusion criteria, he/she is eligible and will be randomly assigned (automatically through electronic version of case report form (eCRF) into two therapy groups (treatment arms).

Investigator performs assessments of: QoL (with questionnaire SF-36), sleep quality and daytime sleepiness (with questionnaires ISI and ESS), depression (with questionnaire MDI) and adverse events.

Administration:

Eligible screened patients are randomly assigned into two therapy groups (treatment arms):

ARM 1: treatment with pregabalin (Pregabalin Krka) or ARM 2: treatment with duloxetine (Dulsevia®).

Each patient receives a Patient diary number 1, including the doses of Pregabalin Krka or Dulsevia® (depending on randomization) from Visit 2 (day 1) till Phone call 1, scales for assessing the pain and with the date of Phone call 1.

Treatment during PERIOD 1 (FLEXIBLE-DOSE REGIMEN during the first 14 days (±3 days) in order to allow the investigator to give each patient an optimal dose of IMP.

  • ARM 1: pregabalin (Pregabalin Krka 25-150 mg/ day) FLEXIBLE-DOSE REGIMEN. Investigator can choose total Pregabalin Krka daily dose: 25 mg/day, 50 mg/day, 75 mg/day, 150 mg/day or 300 mg/day (from Phone call 1 further on)
  • ARM 2: duloxetine (Dulsevia® 30-60 mg/ day) FLEXIBLE-DOSE REGIMEN:

Investigator can choose total Dulsevia® daily dose: 30 mg/day or 60 mg/day

At the Visit 2, RM is given to each patient to cover the treatment till the next Visit 3.

Phone call 1: week 1 (± 3 days) At week 1 (7 ± 3 days after Visit 2) investigator calls the patient by phone and ask him or her about possible adverse events and to evaluate the pain intensity in PDPN by VAS which is a part of Patient diary 1.

Investigator can adjust the dose of IMP during phone call:

  • If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) is NOT achieved, the investigator can increase the dose;
  • if bothersome adverse event occurs the investigator can decrease the dose (if possible).

The investigator also ask the patient if he or she is taking the IMP appropriately (according to investigator's instructions).

NOTE: On the next visit (Visit 3; 14 ± 3 days after Visit 2) following daily doses should be achieved by each patient:

  • ARM 1: Total Pregabalin Krka daily dose: MINIMUM dose 150 mg/day
  • ARM 2: Total Dulsevia daily dose: MINIMUM dose 60 mg/day

Visit 3: week 2 (14 ± 3 days after Visit 2) At Visit 3, compliance monitoring is done, pain intensity in PDPN by VAS is evaluated, concomitant therapy is checked, vital signs are measured, doses of IMP are adjusted and adverse events assessment are carried out.

Investigator collects the Patient Diary 1. Data in Patient Diary 1 are checked.Treatment during PERIOD 2 (it lasts 6 weeks)

Treatment options:

ARM 1: pregabalin (Pregabalin Krka) Investigator can choose: total Pregabalin Krka daily dose: 150 mg/day or 300 mg/day or 600 mg/day

NOTE:

If in the opinion of the investigator the minimum IMP dose of 150 mg of Pregabalin Krka/ 60 mg of Dulsevia® can not be reached after Visit 3, the patient must be excluded from the trial.

ARM 2: duloxetine (Dulsevia®)

Investigator can choose:

  • total Dulsevia® daily dose*: 60 mg/day or 90 mg/day* or total Dulsevia® daily dose**: 120 mg/day

    • once daily dosing by using available dosages. **the daily dose will be achieved with two devided doses of Dulsevia® by using available dosages.

ARM 1: pregabalin (Pregabalin Krka)

  • If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with baseline is achieved during period 1, further treatment with Pregabalin Krka 150 mg/day or 300 mg/day in the period 2 is required.
  • If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with baseline is NOT achieved, further treatment with a dose of:

    • 150 mg/day (if patient was till now treated with equal dose) or 300 mg/day (if patient was till now treated with equal dose to 150 mg or 300 mg) or 600 mg/day (if patient was till now treated with equal dose to 300 mg) is required.

ARM 2: duloxetine (Dulsevia®)

  • If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with baseline is achieved further treatment with Dulsevia® 60 mg/day in the period 2 is required.
  • If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with baseline is NOT achieved, further treatment with the dose of:

    • Dulsevia® 60 mg/day (if patient was till now treated with equal dose) or Dulsevia® 90 mg/day (if patient was till now treated with lower dose) or Dulsevia® 120 mg/day (if patient was till now treted with lower dose) is required.

At the Visit 3, RM is given to each patient to cover the treatment till the next Visit 4. Patient is requested to bring packages with all blisters (empty blisters and blister with unused IMPs and RM) on the Visit 4.

Each patient receives a Patient diary number 2, including the doses of Pregabalin Krka or Dulsevia® (depending on randomization) from Visit 3 till Phone call 2, scales for assessing the pain and with the date of Phone call 2 (28 ± 3 days after Visit 3).

Patient is requested to bring the Patient diary on the next visit.

Information obtained at Visit 3 is input in the eCRF.

Phone call 2: 4 weeks(28 ± 3 days) after visit 3 At week 6 (28 ± 3 days after Visit 3) the investigator again calls the patient by phone and asks him or her about possible bothersome adverse events and to evaluate the pain intensity in PDPN by VAS (separate assessments of current pain intensity, average pain intensity in last 24-h and worst pain intensity in last 24-h) which is a part of Patient diary 2.

The investigator can adjust the dose of Pregabalin Krka or Dulsevia®, if necessary. If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) is NOT achieved the investigator can increase the dose and if bothersome adverse event occurs the investigator can decrease the dose to the previous dose.

The investigator also checks if the patient takes the medicines appropriately (according to investigator's instructions).

Visit 4: week 8 (42 ± 3 days after Visit 3) At Visit 4, pregnancy test for women of childbearing potential and compliance monitoring are carried out; concomitant medications are checked, vital signs are measured, pain intensity in PDPN by VAS is evaluated (separate assessments of current pain intensity, average pain intensity in last 24-h and worst pain intensity in last 24-h, average pain intensity in last 4 weeks and worst pain intensity in last 4 weeks), IMP are adjusted and assessment of adverse events is carried out. Investigator collects the Patient Diary 2. Data in Patient Diary 2 are checked.

Treatment options during PERIOD 3 (it lasts 4 weeks) ARM 1: pregabalin (Pregabalin Krka)

Investigator can choose:

Total Pregabalin Krka daily dose: 75 mg/day *,150 mg/day, 300 mg/day or 600 mg/day

*only in case of bothersome adverse events

ARM 2: duloxetine (Dulsevia®) Investigator can choose:Total Dulsevia® daily dose: 30 mg/day*, 60 mg/day, 90 mg/day or 120 mg/day *only in case of bothersome adverse events

Arm 1: pregabalin (Pregabalin Krka)

  • If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with Visit 3 is achieved, further treatment with previous dose in the period 3 is required.
  • If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with Visit 3 is NOT achieved on daily dose 150 mg, further treatment with a dose of: 150 mg/day (if patient was till now treated with equal dose) or 300 mg/day (if patient was till now treated with lower or equal dose) or 600 mg/day (if patient was till now treted with lower or equal dose) is required.

Arm 2: duloxetine (Dulsevia®)

  • If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with Visit 3 is achieved further treatment with previous dose in the period 3 is required.
  • If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with Visit 3 is NOT achieved, further treatment with a dose of:

Dulsevia® 60 mg/day (if patient was till now treated with equal dose) or Dulsevia® 90 mg/day (if patient was till now treated with lower or equal dose) or Dulsevia® 120 mg/day (if patient was till now treated with lower or equal dose).

At the Visit 4, RM is given to each patient to cover the treatment till the next Visit 5.

Visit 5: week 12 (28 ± 3 days after Visit 4) At Visit 5 investigator performs again assessments of: QoL, sleep quality and daytime sleepiness, depression, cognition and PDPN.

Evaluation of the pain intensity in PDPN by VAS and assessment of the adverse events should be performed.

Pregnancy test for women of childbearing potential is carried out.

Compliance monitoring, measurement of vital signs and concomitant medications are also carryed out by investigator.

02

Conditions studied

  • Painful Diabetic Peripheral Neuropathy
03

In context

Lead sponsor

KRKA is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female and male patients aged 18-85 years.
  2. Patients with a history of type 2 diabetes mellitus according to The American Diabetes Association (ADA).
  3. Patients with a diagnosis of painful diabetic peripheral neuropathy (PDPN) caused by type 2 diabetes mellitus based on DN4 ≥4.
  4. Patients whose average pain intensity in PDPN in last 24 hours (measured by VAS), evaluated on baseline visit, is equal or more than 40 mm (0 mm ='no pain' and 100 mm ='worst possible pain').
  5. Ability to adhere to trial protocol.
  6. Written .

The methods for inclusion criteria assessment include medical history, interview, completing the DN4 questionnaire, physical examination, assesment of pain on VAS and laboratory analyses.

Exclusion criteria

Exclusion Criteria:

  1. Patients who took PDPN medication and/or analgesics on a day of baseline visit.
  2. Patients with a known to duloxetine, pregabalin, paracetamol or tramadol or any of the inactive ingredients or have any for the use of duloxetine, pregabalin, paracetamol or tramadol.
  3. Patients with a history of inadequate pain response (pain reduced was equal or less than 30%) to:

    3.1. pregabalin at maximum allowed treatment daily dose 600 mg, 3.2. duloxetine at maximum allowed treatment daily dose 120 mg, 3.3. venlafaxine at maximum allowed treatment daily dose 375 mg, 3.4. gabapentin on daily treatment dose more than 1800 mg 3.5. amitriptilin at maximum allowed treatment daily dose 150 mg.

  4. Patients, who are currently treated with a daily dose that exceeds:

    4.1. 150 mg of pregabalin, 4.2. 60 mg of duloxetine, 4.3. 150 mg of venlafaxine, 4.4. 600 mg of gabapentin.

  5. Patients with an uncontrolled type 2 diabetes mellitus.
  6. The average scores of less than 20 on .
  7. Have any other type of neuropatic pain, contrasted to PDPN.
  8. Evidence of another cause of distal polyneuropathy other than diabetic.
  9. Have a serious (evaluated by physician) unstable cardiovascular (e.g. uncontrolled hypertension), hepatic, renal, respiratory, ophthalmologic, gastrointestinal, or hematologic illness, symptomatic peripheral vascular disease, malignant disease or other medical condition that could lead to hospitalisation during the course of the trial.
  10. Have a diagnosis or history of uncontrolled glaucoma.
  11. Known or suspected alcohol or drug abuse or addiction (excluding nicotine and caffeine).
  12. Patients with a history of depression (less than one year after completing the last medical treatment), mania, bipolar disorder, psychosis or schizophrenia.
  13. Pregnancy, lactation and women of without highly effective* or at least acceptable** (according to the Recommendations related to contraception and pregnancy testing in clinical trials).
  14. Patients with a history of epilepsy, stroke or neurodegenerative disease.
  15. Patients taking Monoamine oxidase (MAO) inhibitors or are within one year of their withdrawal.
  16. Acute liver injury (such as hepatitis) or severe cirrhosis ( Class C).
  17. Patients with suspected Restless leg syndrome (RLS).
  18. Abnormal thyroid-stimulating hormone (TSH) concentrations (according to the references value of the local laboratory).
  19. Vitamin B12 and folic acid deficiency (according to the reference values of the local laboratory).
  20. Surgical procedures planned to occur during trial (patients may be rescreened following completion of and recovery from the surgical procedure).
  21. Concomitant treatment that might influence the final therapeutic effect of the tested active substances including non-medical treatments.
  22. Patients who under the opinion of the investigator will not be compliant to the treatment or not be able to finish the trial for any other reason.

    • Highly effective contraception is:

      • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation(oral, intravaginal, transdermal)
      • progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
      • intrauterine device (IUD)
      • intrauterine hormone-releasing system (IUS)
      • bilateral tubal occlusion
      • vasectomised partner
      • sexual abstinence

        **Acceptable contraception is:

      • progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
      • male or female condom with or without spermicide
      • cap, diaphragm or sponge with spermicide
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    Pregabalin Krka Arm

    ARM 1: pregabalin (Pregabalin Krka 25-150 mg/ day) FLEXIBLE-DOSE REGIMEN. Investigator can choose on V2: * Total Pregabalin Krka daily dose: 25 mg/day * Total Pregabalin Krka daily dose: 50 mg/day * Total Pregabalin Krka daily dose: 75 mg/day * Total Pregabalin Krka daily dose: 150 mg/day * Total Pregabalin Krka daily dose: 300 mg/day (from Phone call 1 further on) V3: daily dose should be achieved: MINIMUM dose 150 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day V4: Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day

    Drug: Pregabalin

  • Experimental
    Dulsevia® Arm

    • ARM 2: duloxetine (Dulsevia® 30-60 mg/ day) FLEXIBLE-DOSE REGIMEN: Investigator can choose on V2: * Total Dulsevia® daily dose: 30 mg/day * Total Dulsevia® daily dose: 60 mg/day V3: daily dose should be achieved: MINIMUM dose 60 mg/day Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day. V4: Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day.

    Drug: Duloxetine

Interventions

  • Pregabalin Krka (pregabalin) hard capsules of different strenghts: 25 mg, 75 mg, 150 mg, 300 mg. Duration: 12 weeks

  • Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg. Duration: 12 weeks

06

What researchers measure

Primary outcomes

  1. Clinically meaningful improvement of pain in PDPN after a 12 week treatment with pregabalin

    Clinically meaningful improvement of pain in PDPN after a 12 week treatment according to VAS

    Time frame: 12 weeks

  2. Clinically meaningful improvement of pain in PDPN after a 12 week treatment with duloxetine

    Clinically meaningful improvement of pain in PDPN after a 12 week treatment according to VAS

    Time frame: 12 weeks

Secondary outcomes

  1. The proportion of patients with reduction of pain in PDPN for equal or more than 30 % AND/OR with pain intensity in PDPN not exceeding 30 mm

    The proportion of patients with reduction of pain in PDPN (measured by VAS) for equal or more than 30 % AND/OR with pain intensity in PDPN not exceeding 30 mm (measured by VAS) taking into consideration: i. current pain intensity (measured at doctor's office) ii. average pain intensity in last 24-h iii. worst pain intensity in last 24-h

    Time frame: week 1, week 2, week 6, week 8

  2. The proportion of patients with reduction of pain in PDPN for equal or more than 30 % AND/OR with pain intensity in PDPN not exceeding 30 mm

    The proportion of patients with reduction of pain in PDPN for equal or more than 30 % (measured by VAS) AND/OR with pain intensity in PDPN not exceeding 30 mm (measured by VAS) taking into consideration: i. average pain intensity in last 4 weeks ii. worst pain intensity in last 4 weeks

    Time frame: week 8, week 12

  3. Pain intensity difference in PDPN

    Pain intensity difference in PDPN (measured by VAS) between each control visit/ phone call and the baseline value at Visit 2: i. current pain intensity (measured at doctor's office) ii. average pain intensity in last 24-h iii. worst pain intensity in last 24-h

    Time frame: week 1, week 2, week 6, week 8, week 12

  4. Pain intensity difference in PDPN

    Pain intensity difference in PDPN (measured by VAS) between Visits 4 and 5 and the baseline value at Visit 2: i. average pain intensity in last 4 weeks ii. worst pain intensity in last 4 week

    Time frame: week 8, week 12

  5. The proportion of patients with reduction of pain in PDPN for equal or more than 50 %

    The proportion of patients with reduction of pain in PDPN (measured by VAS) for equal or more than 50 % taking into consideration: i. current pain intensity (measured at doctor's office) ii. average pain intensity in last 24-h iii. worst pain intensity in last 24-h

    Time frame: Baseline vs.: week 1, week 2, week 6, week 8, week 12

  6. The proportion of patients with reduction of pain in PDPN for equal or more than 50 %

    The proportion of patients with reduction of pain in PDPN (measured by VAS) for equal or more than 50 % taking into consideration: i. average pain intensity in last 4 weeks ii. worst pain intensity in last 4 weeks

    Time frame: week 8, week 12

  7. The proportion of patients with eliminated pain in PDPN

    The proportion of patients with eliminated pain in PDPN, which includes intensity of pain in PDPN not exceeding 10 mm (measured by VAS) taking into consideration: i. current pain intensity (measured at doctor's office) ii. average pain intensity in last 24-h iii. worst pain intensity in last 24-h

    Time frame: week 6, week 8, week 12

  8. The proportion of patients with eliminated pain in PDPN

    The proportion of patients with eliminated pain in PDPN, which includes intensity of pain in PDPN not exceeding 10 mm (measured by VAS) taking into consideration: i. average pain intensity in last 4 weeks ii. worst pain intensity in last 4 weeks

    Time frame: week 8, week 12

  9. Dose-related efficacy

    Changes of efficacy according to changing of doses

    Time frame: week 2, week 8, week 12

  10. DN4 score difference

    Mean changes of scores

    Time frame: baseline, week 12

  11. Quality of life (QoL) difference with 36-Item Short Form Survey Instrument (SF-36)

    Mean changes of scores

    Time frame: baseline, week 12

  12. The Montreal Cognitive Assessment (MoCA) score difference for cognitive improvement

    Mean changes of scores

    Time frame: week 1, week 12

  13. Insomnia severity index (ISI) difference for sleep

    Mean changes of scores

    Time frame: baseline, week 12

  14. Epworth Sleepiness Scale (ESS) score for daytime sleepiness improvement

    Mean changes of scores

    Time frame: baseline, week 12

  15. Major depression inventory (MDI) score difference for improvement of major depression

    Mean changes of scores

    Time frame: baseline, week 12

  16. Proportion of compliant patients

    Proportion of compliant patients, i.e. those having a compliance of more than 80 % at the regular therapy end visit

    Time frame: week 2, week 8, week 12

07

Study locations

13 sites
  • Opća bolnica Karlovac
    Karlovac, Croatia
  • Clinical Medical Center Osijek
    Osijek, Croatia
  • KB Merkur, Sveučilišna klinika Vuk Vrhovac
    Zagreb, Croatia
  • Klinička bolnica Sveti Duh
    Zagreb, Croatia
  • JZU Univerzitetska klinika za endokrinologija, dijabetes I metabolicki bolesti - Skopje
    Skopje, North Macedonia
  • JZU Univerzitetska klinika za nevrologija
    Skopje, North Macedonia
  • Gabinet Neurologiczny, prof. Adam Stępień
    Warszawa, Poland
  • Poradnia neurologiczna, Centrum terapii dzieci i Dorosłych FIMEDICA Sp. z o.o.
    Warszawa, Poland
  • Klinički centar Srbije
    Belgrade, Serbia
  • Klinički centar Niš
    Niš, Serbia
  • Klinički centar Vojvodine
    Novi Sad, Serbia
  • Zdravstveni dom Koper
    Koper, 6000, Slovenia
  • Clemenz Marjetka - Nevrološka Ordinacija
    Ljubljana, 1000, Slovenia
08

References and documents

Publications

  • Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45 Suppl 6:13-8. doi: 10.1111/j.0013-9580.2004.455003.x. PubMed 15315511 ↗
  • Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007 Jan;29(1):26-48. doi: 10.1016/j.clinthera.2007.01.013. PubMed 17379045 ↗
  • Schulze-Bonhage A. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2013 Jan;9(1):105-15. doi: 10.1517/17425255.2013.749239. Epub 2012 Dec 4. PubMed 23205518 ↗
  • Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010 Oct;49(10):661-9. doi: 10.2165/11536200-000000000-00000. PubMed 20818832 ↗
  • Goldstein DJ. Duloxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007 Apr;3(2):193-209. doi: 10.2147/nedt.2007.3.2.193. PubMed 19300553 ↗
  • Perahia DG, Pritchett YL, Desaiah D, Raskin J. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol. 2006 Nov;21(6):311-7. doi: 10.1097/01.yic.0000224782.83287.3c. PubMed 17012978 ↗
  • Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004 Dec 14;63(11):2104-10. doi: 10.1212/01.wnl.0000145767.36287.a1. PubMed 15596757 ↗
  • Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004 Aug;110(3):628-638. doi: 10.1016/j.pain.2004.05.001. PubMed 15288403 ↗
  • Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005 Apr;6(4):253-60. doi: 10.1016/j.jpain.2004.12.007. PubMed 15820913 ↗
  • Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008 Feb;12(2):203-13. doi: 10.1016/j.ejpain.2007.05.003. Epub 2007 Jul 16. PubMed 17631400 ↗
  • Razazian N, Baziyar M, Moradian N, Afshari D, Bostani A, Mahmoodi M. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial. Neurosciences (Riyadh). 2014 Jul;19(3):192-8. PubMed 24983280 ↗
  • Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005 Jun;115(3):254-263. doi: 10.1016/j.pain.2005.02.032. Epub 2005 Apr 18. PubMed 15911152 ↗
  • Lindsay TJ, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician. 2010 Jul 15;82(2):151-8. PubMed 20642268 ↗
  • Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005 Jul;116(1-2):109-18. doi: 10.1016/j.pain.2005.03.029. PubMed 15927394 ↗
  • Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005 Sep-Oct;6(5):346-56. doi: 10.1111/j.1526-4637.2005.00061.x. PubMed 16266355 ↗
  • Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, Raskin J. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006 Oct 24;67(8):1411-20. doi: 10.1212/01.wnl.0000240225.04000.1a. PubMed 17060567 ↗
  • Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med. 2006 Sep-Oct;7(5):373-85. doi: 10.1111/j.1526-4637.2006.00207.x. PubMed 17014595 ↗
  • Wernicke JF, Raskin J, Rosen A, Pritchett YL, D'Souza DN, Iyengar S, Knopp K, Le TK. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial. Curr Ther Res Clin Exp. 2006 Sep;67(5):283-304. doi: 10.1016/j.curtheres.2006.10.001. PubMed 24678103 ↗
  • Smith T, Nicholson RA. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag. 2007;3(6):833-44. PubMed 18200804 ↗
  • Wernicke JF, Prakash A, Kajdasz DK, Houston J. Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. J Diabetes Complications. 2009 Sep-Oct;23(5):349-59. doi: 10.1016/j.jdiacomp.2008.07.004. Epub 2008 Sep 2. PubMed 18768332 ↗
  • Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010 Sep;17(9):1113-e88. doi: 10.1111/j.1468-1331.2010.02999.x. Epub 2010 Apr 9. PubMed 20402746 ↗
  • Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother. 2005 Dec;39(12):2029-37. doi: 10.1345/aph.1G078. Epub 2005 Nov 15. PubMed 16288079 ↗
  • Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014 Jan 3;2014(1):CD007115. doi: 10.1002/14651858.CD007115.pub3. PubMed 24385423 ↗
  • Del Casale A, Girardi P, Brugnoli R, Sani G, Di Pietro S, Brugnoli C, Caccia F, Angeletti G, Serata D, Rapinesi C, Tatarelli R, Kotzalidis GD. Duloxetine in the treatment of elderly people with major depressive disorder. Riv Psichiatr. 2012 Nov-Dec;47(6):479-88. doi: 10.1708/1178.13054. PubMed 23160108 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Dec 2021, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2020
First posted
Jan 29, 2020
StartActual
Nov 12, 2019
Primary completionActual
Dec 21, 2021
CompletionActual
Dec 21, 2021
Last update
Apr 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04246619
Lead sponsor
KRKA
Collaborators
3ARH, INTERBORA, University Medical Centre Maribor
Responsible party
Sponsor
First posted
Jan 29, 2020
Start date
Nov 12, 2019
Primary completion
Dec 21, 2021
Completion
Dec 21, 2021
Last update
Apr 7, 2022

Study contacts

Martin Rakuša
study chair · University Medical Centre Maribor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pregabalin · Duloxetine

Start the discussion